Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billionPUBT·15 hours ago02196+1.15%00656+1.80%
As weight-loss drug orders surge, global funds pile into China’s WuXi AppTecSCMP·Jul 24 at 05:39 AM02359+0.19%603259-0.79%
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Receives a Buy from CitiTip Ranks·Jul 22 at 07:27 PM03347-0.36%300347-0.57%
China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New HighAASTOCKS News·Jul 20 at 01:00 AM510660-0.20%159992-0.59%
WuXi AppTec joins FTSE4Good Index Series for fourth straight yearPUBT·Jul 21 at 06:54 PM02359+0.19%603259-0.79%
Chinese biotech overtakes AI as emerging-market growth tradeBusinesstimes News·2 days ago, 10:14 PM300765+0.50%AZN+0.48%
China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global TotalAASTOCKS News·Jul 20 at 01:00 AM513060+0.37%159859-0.26%
Virax Biolabs signs Fosun Diagnostics supply deal for ImmuneSelect in six Southeast Asian marketsPUBT·Jul 16 at 06:33 AMVRAX+1.38%02196+1.15%
Fosun Pharma Shenzhen wins China approval to start Phase I trial of FXR0906 for hypertriglyceridemiaPUBT·Jul 15 at 05:14 AM02196+1.15%600196+4.00%
China's 1H25 Innovative Drug Out-Licensing Deal Value Rises to USD110 Billion, Hitting Fresh Record HighAASTOCKS News·Jul 13 at 04:25 AM159837-0.21%159859-0.26%
UBS: CN CRO Sees Solid Revenue Growth in 1H; WUXI APPTEC Top PickAASTOCKS News·Jul 14 at 02:56 AM02269+0.41%02359+0.19%
UBS' Investment Ratings and TPs on CRO Stocks (Table)AASTOCKS News·Jul 14 at 02:00 AM300759-1.40%022680.00%
CLSA Sticks to Its Buy Rating for WuXi AppTec Co., Ltd. Class H (2359)Tip Ranks·Jul 16 at 07:26 PM02359+0.19%603259-0.79%
China's Outbound Licensing of Innovative Drugs in First Half Nears Last Year's TotalYicai·Jul 13 at 02:28 AM159859-0.26%513700+0.51%
HSI Up 340 pts; HSTI Up 61 pts; MEITUAN Up over 5%; TENCENT Up over 3%; WUXI APPTEC, HSBC HOLDINGS, ABLE DIGITAL Hit New Highs; Market Turnover RisesAASTOCKS News·Jul 15 at 03:20 AM03690+1.08%02359+0.19%
